Sequence information
DRAVP ID DRAVPc031
Name Maftivimab(REGN-3479)
Sequence Not available
Molecular Formula C6368H9886N1706O2008S46
Condition/Disease Zaire ebolavirus infection
Group Approved
Type Antibody
Description Maftivimab is part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.Maftivimab is indicated in combination with Odesivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.
Active sequence/Structure
External Links
DrugBank Accession Number DB15899
Pubchem ID 381609201
CHEMBL ID CHEMBL4298184
UNII KOP95331M4
CAS 2135632-36-7
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT03576690 | R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease | Ebolavirus Disease | Available | Not Available | Regeneron Pharmaceuticals |
| NCT05202288 | Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers | Ebolavirus Disease Prevention | Not yet recruiting | Phase 2 | ANRS, Emerging Infectious Diseases |
